Urokinase-type plasminogen activator and arthritis progression: Contrasting roles in systemic and monoarticular arthritis models

Arthritis Research and Therapy

Volumn 12, Issue 5, 2010, Pages

  De Nardo, Christine M ^a   Lenzo, Jason C ^a   Pobjoy, Jarrad ^a   Hamilton, John A ^a   Cook, Andrew D ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE 1; AGGRECANASE 2; ANTIGEN; FIBRINOGEN; INTERLEUKIN 1BETA; MATRIX METALLOPROTEINASE; PROTEOGLYCAN; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR; UROKINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN ANTIBODY COMPLEX; ARTHRITIS; ARTICLE; BONE DESTRUCTION; BONE EROSION; CARTILAGE DEGENERATION; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DISEASE SEVERITY; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; MONARTHRITIS; MOUSE; NONHUMAN; PATHOGENESIS; POLYARTHRITIS; POLYMERASE CHAIN REACTION; QUANTITATIVE ANALYSIS; ANIMAL; C57BL MOUSE; FEMALE; GENE EXPRESSION PROFILING; IMMUNOLOGY; MALE; METABOLISM; MOUSE MUTANT; PATHOLOGY; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION PROFILING; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 77958144272     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3171     Document Type: Article

References (45)

1. Irigoyen JP, Munoz-Canoves P, Montero L, Koziczak M, Nagamine Y. The plasminogen activator system: biology and regulation. Cell Mol Life Sci 1999, 56:104-132. 10.1007/PL00000615, 11213252.
2. Busso N, Hamilton JA. Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis. Arthritis Rheum 2002, 46:2268-2279. 10.1002/art.10498, 12355473.
3. Cook AD, Braine EL, Campbell IK, Hamilton JA. Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. Am J Pathol 2002, 160:917-926. 1867189, 11891190.
4. Cook AD, De Nardo CM, Braine EL, Turner AL, Vlahos R, Way KJ, Beckman SK, Lenzo JC, Hamilton JA. Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement. Arthritis Res Ther 2010, 12:R37. 10.1186/ar2946, 2888184, 20196869.
5. Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol 2005, 166:783-792. 1602367, 15743790.
6. Busso N, Peclat V, Van Ness K, Kolodziesczyk E, Degen J, Bugge T, So A. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J Clin Invest 1998, 102:41-50. 10.1172/JCI2312, 509063, 9649555.
7. Yang YH, Carmeliet P, Hamilton JA. Tissue-type plasminogen activator deficiency exacerbates arthritis. J Immunol 2001, 167:1047-1052.
8. Werd Z, Alexander CM. Proteinases and Matrix Degradation 1993, 248-268. Philadelphia, PA: W.B. Saunders Co.
9. Murphy G, Atkinson S, Ward R, Gavrilovic J, Reynolds JJ. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann N Y Acad Sci 1992, 667:1-12. 10.1111/j.1749-6632.1992.tb51590.x, 1339240.
10. Werb Z, Mainardi CL, Vater CA, Harris ED. Endogenous activiation of latent collagenase by rheumatoid synovial cells. Evidence for a role of plasminogen activator. N Engl J Med 1977, 296:1017-1023. 10.1056/NEJM197705052961801, 66627.
11. Campbell IK, Last K, Novak U, Lund LR, Hamilton JA. Recombinant human interleukin-1 inhibits plasminogen activator inhibitor-1 (PAI-1) production by human articular cartilage and chondrocytes. Biochem Biophys Res Commun 1991, 174:251-257. 10.1016/0006-291X(91)90513-7, 1989604.
12. Campbell IK, Piccoli DS, Butler DM, Singleton DK, Hamilton JA. Recombinant human interleukin-1 stimulates human articular cartilage to undergo resorption and human chondrocytes to produce both tissue- and urokinase-type plasminogen activator. Biochim Biophys Acta 1988, 967:183-194.
13. Hamilton JA, Campbell IK, Wojta J, Cheung D. Plasminogen activators and their inhibitors in arthritic disease. Ann N Y Acad Sci 1992, 667:87-100. 10.1111/j.1749-6632.1992.tb51602.x, 1309075.
14. Hamilton JA, Cheung D, Filonzi EL, Piccoli DS, Wojta J, Gallichio M, McGrath K, Last K. Independent regulation of plasminogen activator inhibitor 2 and plasminogen activator inhibitor 1 in human synovial fibroblasts. Arthritis Rheum 1992, 35:1526-1534. 10.1002/art.1780351217, 1472130.
15. Hamilton JA, Hart PH, Leizer T, Vitti GF, Campbell IK. Regulation of plasminogen activator activity in arthritic joints. J Rheumatol Suppl 1991, 27:106-109.
16. Hamilton JA, Slywka J. Stimulation of human synovial fibroblast plasminogen activator production by mononuclear cell supernatants. J Immunol 1981, 126:851-855.
17. Hamilton JA, Stanley ER, Burgess AW, Shadduck RK. Stimulation of macrophage plasminogen activator activity by colony-stimulating factors. J Cell Physiol 1980, 103:435-445. 10.1002/jcp.1041030309, 6967488.
18. Leizer T, Clarris BJ, Ash PE, van Damme J, Saklatvala J, Hamilton JA. Interleukin-1 beta and interleukin-1 alpha stimulate the plasminogen activator activity and prostaglandin E2 levels of human synovial cells. Arthritis Rheum 1987, 30:562-566. 10.1002/art.1780300511, 3109443.
19. Ronday HK, Smits HH, Quax PH, van der Pluijm G, Lowik CW, Breedveld FC, Verheijen JH. Bone matrix degradation by the plasminogen activation system. Possible mechanism of bone destruction in arthritis. Br J Rheumatol 1997, 36:9-15. 10.1093/rheumatology/36.1.9, 9117184.
20. van der Laan WH, Pap T, Ronday HK, Grimbergen JM, Huisman LG, TeKoppele JM, Breedveld FC, Gay RE, Gay S, Huizinga TW, Verheijen JH, Quax PH. Cartilage degradation and invasion by rheumatoid synovial fibroblasts is inhibited by gene transfer of a cell surface-targeted plasmin inhibitor. Arthritis Rheum 2000, 43:1710-1718. 10.1002/1529-0131(200008)43:8<1710::AID-ANR6>3.0.CO;2-Y, 10943860.
21. Li J, Guo Y, Holmdahl R, Ny T. Contrasting roles of plasminogen deficiency in different rheumatoid arthritis models. Arthritis Rheum 2005, 52:2541-2548. 10.1002/art.21229, 16052596.
22. Kouskoff V, Korganow AS, Duchatelle V, Degott C, Benoist C, Mathis D. Organ-specific disease provoked by systemic autoimmunity. Cell 1996, 87:811-822. 10.1016/S0092-8674(00)81989-3, 8945509.
23. Little CB, Barai A, Burkhardt D, Smith SM, Fosang AJ, Werb Z, Shah M, Thompson EW. Matrix metalloproteinase 13-deficient mice are resistant to osteoarthritic cartilage erosion but not chondrocyte hypertrophy or osteophyte development. Arthritis Rheum 2009, 60:3723-3733. 10.1002/art.25002, 19950295.
24. Mercuri FA, Maciewicz RA, Tart J, Last K, Fosang AJ. Mutations in the interglobular domain of aggrecan alter matrix metalloproteinase and aggrecanase cleavage patterns. Evidence that matrix metalloproteinase cleavage interferes with aggrecanase activity. J Biol Chem 2000, 275:33038-33045. 10.1074/jbc.275.42.33038, 11032846.
25. Lawlor KE, Campbell IK, O'Donnell K, Wu L, Wicks IP. Molecular and cellular mediators of interleukin-1-dependent acute inflammatory arthritis. Arthritis Rheum 2001, 44:442-450. 10.1002/1529-0131(200102)44:2<442::AID-ANR63>3.0.CO;2-M, 11229476.
26. Milner JM, Rowan AD, Cawston TE, Young DA. Metalloproteinase and inhibitor expression profiling of resorbing cartilage reveals pro-collagenase activation as a critical step for collagenolysis. Arthritis Res Ther 2006, 8:R142. 10.1186/ar2034, 1779431, 16919164.
27. Moilanen M, Sorsa T, Stenman M, Nyberg P, Lindy O, Vesterinen J, Paju A, Konttinen YT, Stenman UH, Salo T. Tumor-associated trypsinogen-2 (trypsinogen-2) activates procollagenases (MMP-1, -8, -13) and stromelysin-1 (MMP-3) and degrades type I collagen. Biochemistry 2003, 42:5414-5420. 10.1021/bi020582s, 12731883.
28. Birkedal-Hansen H, Lin HY, Birkedal-Hansen B, Windsor LJ, Pierson MC. Degradation of collagen fibrils by live cells: role of expression and activation of procollagenase. Matrix Suppl 1992, 1:368-374.
29. Milner JM, Elliott SF, Cawston TE. Activation of procollagenases is a key control point in cartilage collagen degradation: interaction of serine and metalloproteinase pathways. Arthritis Rheum 2001, 44:2084-2096. 10.1002/1529-0131(200109)44:9<2084::AID-ART359>3.0.CO;2-R, 11592371.
30. van Lent PL, Holthuysen AE, Sloetjes A, Lubberts E, van den Berg WB. Local overexpression of adeno-viral IL-4 protects cartilage from metallo proteinase-induced destruction during immune complex-mediated arthritis by preventing activation of pro-MMPs. Osteoarthritis Cartilage 2002, 10:234-243. 10.1053/joca.2001.0501, 11869085.
31. Jin T, Tarkowski A, Carmeliet P, Bokarewa M. Urokinase, a constitutive component of the inflamed synovial fluid, induces arthritis. Arthritis Res Ther 2003, 5:R9-R17. 10.1186/ar606, 154426, 12716448.
32. Monach P, Hattori K, Huang H, Hyatt E, Morse J, Nguyen L, Ortiz-Lopez A, Wu HJ, Mathis D, Benoist C. The K/BxN mouse model of inflammatory arthritis: theory and practice. Methods Mol Med 2007, 136:269-282. full_text, 17983155.
33. Bugge TH, Flick MJ, Danton MJ, Daugherty CC, Romer J, Dano K, Carmeliet P, Collen D, Degen JL. Urokinase-type plasminogen activator is effective in fibrin clearance in the absence of its receptor or tissue-type plasminogen activator. Proc Natl Acad Sci USA 1996, 93:5899-5904. 10.1073/pnas.93.12.5899, 39159, 8650190.
34. Romer J, Bugge TH, Pyke C, Lund LR, Flick MJ, Degen JL, Dano K. Impaired wound healing in mice with a disrupted plasminogen gene. Nat Med 1996, 2:287-292. 10.1038/nm0396-287, 8612226.
35. Flick MJ, LaJeunesse CM, Talmage KE, Witte DP, Palumbo JS, Pinkerton MD, Thornton S, Degen JL. Fibrin(ogen) exacerbates inflammatory joint disease through a mechanism linked to the integrin alphaMbeta2 binding motif. J Clin Invest 2007, 117:3224-3235. 10.1172/JCI30134, 2000806, 17932565.
36. Bryer SC, Fantuzzi G, Van Rooijen N, Koh TJ. Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration. J Immunol 2008, 180:1179-1188.
37. Minami E, Castellani C, Malchodi L, Deem J, Bertko K, Meznarich J, Dishmon M, Murry CE, Stempien-Otero A. The role of macrophage-derived urokinase plasminogen activator in myocardial infarct repair: Urokinase attenuates ventricular remodeling. J Mol Cell Cardiol 2010, 49:516-524. 10.1016/j.yjmcc.2010.03.022, 20380835.
38. Tortorella MD, Malfait AM, Deccico C, Arner E. The role of ADAM-TS4 (aggrecanase-1) and ADAM-TS5 (aggrecanase-2) in a model of cartilage degradation. Osteoarthritis Cartilage 2001, 9:539-552. 10.1053/joca.2001.0427, 11520168.
39. Martel-Pelletier J, McCollum R, Fujimoto N, Obata K, Cloutier JM, Pelletier JP. Excess of metalloproteases over tissue inhibitor of metalloprotease may contribute to cartilage degradation in osteoarthritis and rheumatoid arthritis. Lab Invest 1994, 70:807-815.
40. Kusano K, Miyaura C, Inada M, Tamura T, Ito A, Nagase H, Kamoi K, Suda T. Regulation of matrix metalloproteinases (MMP-2, -3, -9, and -13) by interleukin-1 and interleukin-6 in mouse calvaria: association of MMP induction with bone resorption. Endocrinology 1998, 139:1338-1345. 10.1210/en.139.3.1338, 9492070.
41. van den Berg WB, van de Loo FA, van Lent PL, Joosten LA. Mechanisms of cartilage destruction in joint inflammation. Agents Actions Suppl 1993, 39:49-60. 10.1007/BF01975714, 8456643.
42. Konig A, Muhlbauer RC, Fleisch H. Tumor necrosis factor alpha and interleukin-1 stimulate bone resorption in vivo as measured by urinary [3H]tetracycline excretion from prelabeled mice. J Bone Miner Res 1988, 3:621-627. 10.1002/jbmr.5650030607, 3266953.
43. Kang BS, Park YG, Cho JY, Kim JK, Lee TK, Kim DW, Gu YH, Suzuki I, Chang YC, Kim CH. Interleukin-1 and tumor necrosis factor-alpha induce collagenolysis and bone resorption by regulation of matrix metalloproteinase-2 in mouse calvarial bone cells. Immunopharmacol Immunotoxicol 2003, 25:347-364. 10.1081/IPH-120024503, 19180798.
44. Cook AD, Vlahos R, Massa CM, Braine EL, Lenzo JC, Turner AL, Way KJ, Hamilton JA. The effect of tissue type-plasminogen activator deletion and associated fibrin(ogen) deposition on macrophage localization in peritoneal inflammation. Thromb Haemost 2006, 95:659-667.
45. Wahl SM, Arend WP, Ross R. The effect of complement depletion on wound healing. Am J Pathol 1974, 75:73-89. 1910809, 4825618.